A Case of Severe, Refractory Hypotension After Amlodipine Overdose.

Cardiovasc Toxicol

Tampa General Hospital, 1 Tampa General Circle, Tampa, FL, 33606, USA.

Published: April 2018

AI Article Synopsis

  • Calcium channel blockers (CCBs), particularly amlodipine, can lead to severe complications and mortality in overdose cases, as demonstrated by a 53-year-old male who ingested eighty 10 mg tablets in a suicide attempt.
  • Despite aggressive treatments including calcium boluses, glucagon, lipid emulsions, and methylene blue, the patient's hypotension was resistant, eventually requiring plasmapheresis and extracorporeal membrane oxygenation (ECMO) to stabilize his condition.
  • Ultimately, following a critical episode that led to brain injury, the family opted to withdraw medical care, underscoring the challenges and limited existing literature on managing severe CCB overdoses.

Article Abstract

Calcium channel blockers (CCBs) are responsible for a substantial portion of the mortality associated with cardiovascular medication overdose cases. Amlodipine, a dihydropyridine CCB, can cause prolonged hypotension in overdose. This report describes a severe amlodipine overdose case that was refractory to multiple therapeutic approaches. A 53-year-old male presented after ingesting eighty 10 mg amlodipine tablets in a suicide attempt. The patient was initially managed with calcium boluses, glucagon, multiple vasoactive agents, lipid emulsion infusions and hyperinsulinemic euglycemic therapy. Methylene blue boluses were initiated when hypotension persisted despite conventional treatments. Refractory hypotension prompted the use of plasmapheresis in an attempt to lower serum amlodipine levels. Finally, the patient was placed on extracorporeal membrane oxygenation (ECMO) to maintain perfusion while the effects of the amlodipine ingestion dissipated. Following an episode of asystole and pulseless electrical activity prior to the start of ECMO, the patient suffered an anoxic brain injury and suspected herniation prompting the family to withdraw medical care. There is limited evidence in the literature describing the refractory treatment modalities utilized in this patient. This report is unique as it describes the clinical course of a patient when a multitude of unique treatments were combined.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12012-017-9419-xDOI Listing

Publication Analysis

Top Keywords

refractory hypotension
8
amlodipine overdose
8
amlodipine
6
patient
5
case severe
4
refractory
4
severe refractory
4
hypotension
4
hypotension amlodipine
4
overdose
4

Similar Publications

Oral blood pressure augmenting agents for intravenous vasopressor weaning.

World J Clin Cases

December 2024

Department of Anesthesiology, Mayo Clinic, Rochester, MN 55905, United States.

Intravenous (IV) vasopressors are essential in the management of hypotension and shock. Initiation of oral vasoactive agents to facilitate weaning of IV vasopressors to liberate patients from the intensive care unit is common despite conflicting evidence regarding the benefits of this practice. While midodrine appears to be the most frequently studied oral vasoactive agent for this purpose, its adverse effect profile may preclude its use in certain populations.

View Article and Find Full Text PDF

Background: CD19 CAR T-cell therapy is a novel anti-cancer treatment that has produced remarkable responses in relapsed or refractory B-cell hematological malignancies. Cytokine Release Syndrome (CRS) is a dysregulated immune response that frequently occurs after CAR T-cell infusion. It can cause cardiac dysfunction and circulatory collapse negatively impacting outcomes and survival.

View Article and Find Full Text PDF

Background: The humanized anti-disialoganglioside-2 monoclonal antibody naxitamab was approved in the USA in 2020 for the treatment of patients with relapsed/refractory high-risk neuroblastoma, limited to the bone or bone marrow, in combination with granulocyte-macrophage colony-stimulating factor. Treatment with naxitamab under expanded access was initiated by physicians from the Children's Hospital of Fudan University, Shanghai, China, in August 2021.

Objective: We reviewed all suspected adverse reactions (ARs) reported to the Y-mAbs Argus Global Pharmacovigilance Safety Database for patients treated with naxitamab under expanded access in China from 1 August 2021 to 31 July 2022.

View Article and Find Full Text PDF

Strategies to innovate emergency care of status epilepticus.

Neurotherapeutics

December 2024

Department of Neurology and Neuroscience Brain Institute University of Virginia, School of Medicine, Health Sciences Center, Box 801330, Charlottesville, VA 22908-1330, USA. Electronic address:

Generalized Convulsive status epilepticus (SE) is a neurological emergency because prolonged convulsions can cause respiratory compromise and neuronal injury. Compromised GABA-mediated inhibition is a defining feature of SE, and many current therapies are benzodiazepines, which are allosteric modulators of GABA-A receptors. Many patients with medically refractory epilepsy are at risk for SE.

View Article and Find Full Text PDF

Coingestion of cardiovascular drugs with angiotensin-converting enzyme inhibitors (ACEIs) can be associated with refractory shock derangements complicated by vasopressor resistance, prompting the use of novel, unconventional, or uncommonly used agents. A young adult male presented to the emergency department (ED) 10 h after ingesting lisinopril and amlodipine. On arrival, he was hypotensive with a blood pressure of 72/39 mmHg.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!